文献速递膀胱癌与上尿路尿路上皮癌

比较原发性和继发性肌层浸润性膀胱癌行根治性膀胱切除术联合或不联合新辅助化疗的病理与生存结局

Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy.
PubMed 文献 · Urology · 2022-06-28

本研究回顾性分析2010—2019年本机构333例cT2-T4/N0肌层浸润性膀胱癌患者,比较原发性(285例)与继发性(48例)患者接受顺铂类新辅助化疗联合根治性膀胱切除术后的病理降期率、病理完全缓解率及生存结局,发现两组间无差异;仅接受根治性膀胱切除术的继发性患者(61例)肿瘤学结局较差。

要点

  • 继发性肌层浸润性膀胱癌48例与原发285例相比,病理降期率(54% vs 51%,P=.67)和病理完全缓解率(33% vs 28%,P=.46)无差异。
  • 接受新辅助化疗联合根治性膀胱切除术的患者中,原发与继发性肌层浸润性膀胱癌的生存结局无差异。
  • 仅接受根治性膀胱切除术的继发性肌层浸润性膀胱癌患者(61例)肿瘤学结局较其他队列差(P<.01)。

核心结论

  • 原发性和继发性肌层浸润性膀胱癌患者接受新辅助化疗联合根治性膀胱切除术时,病理缓解和生存结局无差异。

研究设计与样本

  • 回顾性分析本机构2010—2019年cT2-T4/N0肌层浸润性膀胱癌患者,共333例(继发性48例 vs 原发性285例)。
  • 继发性肌层浸润性膀胱癌定义为既往非肌层浸润性膀胱癌接受至少一个诱导疗程卡介苗治疗后进展为肌层浸润性膀胱癌。
  • 原发性和继发性肌层浸润性膀胱癌患者接受或不接受顺铂类新辅助化疗后行根治性膀胱切除术。

主要发现

  • 病理降期率继发性54% vs 原发性51%(P=.67),病理完全缓解率继发性33% vs 原发性28%(P=.46)。
  • 接受新辅助化疗联合根治性膀胱切除术的患者中,原发性和继发性肌层浸润性膀胱癌的肿瘤学结局无差异。
  • 回归分析中仅>pT2和N+疾病是较差癌症特异性生存和总生存的预测因素。
  • 仅接受根治性膀胱切除术的继发性肌层浸润性膀胱癌患者(N=61)肿瘤学结局较其他队列差(P<.01)。

关键数值与推荐

  • 病理降期定义为<pT2/N0。
  • 病理完全缓解定义为pT0/N0。
  • 生存结局包括无复发生存、癌症特异性生存和总生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare pathologic and survival outcomes between primary muscle invasive (pMIBC) and secondary muscle invasive (sMIBC) bladder cancer patients who were treated with or without cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). METHODS: We reviewed cT2-T4/N0 MIBC patients at our institution between 2010-2019. pMIBC was defined as presenting with > cT2 disease on initial or restaging TURBT with no prior history of bladder cancer. sMIBC was defined as prior history of NMIBC that was treated with at least one induction course of BCG that progressed to MIBC. Outcomes analyzed included pathologic downstaging rates defined as <pT2/N0, pathologic complete response rates (pT0/N0), and survival outcomes (RFS, CSS, OS). Survival outcomes were analyzed using the Kaplan-Meier Method or Gray's test with log rank. Cox Proportional Hazards and semiparametric hazards models proposed by Fine and Gray were constructed to identify predictors of oncologic outcomes. RESULTS: 333 patients were included in the analysis (sMIBC: 48 vs pMIBC: 285). There were no differences in pathologic downstaging (sMIBC: 54% vs pMIBC: 51%, P = .67) or pathologic complete response (sMIBC: 33% vs pMIBC: 28, P = .46). Survival analysis showed no differences when patients were treated with NAC+RC in oncologic outcomes. On regression analysis, only >pT2 and N+ disease were predictors of poorer CSS and OS. Separate analysis of sMIBC patients whom underwent RC only (N = 61), demonstrated inferior oncologic outcomes to other cohorts (P < .01). CONCLUSION: There were no differences in pathologic response or survival between pMIBC and sMIBC patients when managed with NAC and RC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Benidir T, Lone Z, Zhang A, et al. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy. Urology. 2022. PMID: 35772481. doi:10.1016/j.urology.2022.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。